--- schema_version: "secwatch.filing_event.v1" accession: "0001193125-26-270330" form_type: "8-K" ticker: "SNSE" cik: "0001829802" company_name: "Sensei Biotherapeutics, Inc." filed_at: "2026-06-15T12:16:14+00:00" generated_at: "2026-06-15T12:20:11.738132+00:00" event_type: "other_material" sentiment: "positive" materiality_score: 0.85 calibrated_materiality_score: 0.85 confidence: "high" source: SEC EDGAR --- # Faeth Therapeutics (fka Sensei) appoints new CEO, CFO; PIKTOR Phase 2 data expected H2 2026 ## Summary - Name changed to Faeth Therapeutics; ticker to FTH effective June 16, 2026; Austin HQ. - Anand Parikh appointed Chairman, President & CEO; Brian Stephenson appointed CFO. - Board adds former FDA Commissioner Stephen M. Hahn and Saira Ramasastry. - Series B preferred stock converted; $200M gross proceeds from Feb 2026 private placement. - PIKTOR (oral PI3K/AKT/mTOR inhibitor) Phase 2 topline data in advanced endometrial cancer expected H2 2026. ## SEC filing metadata - accession: 0001193125-26-270330 - form_type: 8-K - ticker: SNSE - cik: 0001829802 - company_name: Sensei Biotherapeutics, Inc. - filed_at: 2026-06-15T12:16:14+00:00 - event_type: other_material - sentiment: positive - materiality_score: 0.85 - calibrated_materiality_score: 0.85 - confidence: high - sec_items: 1.02, 5.02, 5.03, 7.01, 8.01, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1829802/000119312526270330/0001193125-26-270330-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829802/000119312526270330/d144622d8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001193125-26-270330 - JSON: https://secwatch.observer/filing/0001193125-26-270330.json - Plain text: https://secwatch.observer/filing/0001193125-26-270330.txt ## Key facts - Executive change Anand Parikh was appointed as President and Chief Executive Officer at Sensei Biotherapeutics, Inc.. - Action: appointed - Role: President and Chief Executive Officer source text: The Board of Directors (the “Board”) of the Company appointed Anand Parikh as President and Chief Executive Officer of the Company, effective as of June 13, 2026 evidence_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312526270330/0001193125-26-270330-index.htm - Executive change Brian Stephenson was appointed as Chief Financial Officer at Sensei Biotherapeutics, Inc.. - Action: appointed - Role: Chief Financial Officer source text: Effective as of June 13, 2026, Brian Stephenson was appointed as the Company’s Chief Financial Officer and principal financial officer. evidence_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312526270330/0001193125-26-270330-index.htm - Executive change Thomas Ricks resigned as Director at Sensei Biotherapeutics, Inc.. - Action: resigned - Role: Director source text: effective as of June 12, 2026, Christopher W. Gerry, Thomas Ricks and Kristian Humer resigned from the Board. evidence_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312526270330/0001193125-26-270330-index.htm - Executive change Christopher W. Gerry resigned as Director at Sensei Biotherapeutics, Inc.. - Action: resigned - Role: Director source text: effective as of June 12, 2026, Christopher W. Gerry, Thomas Ricks and Kristian Humer resigned from the Board. evidence_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312526270330/0001193125-26-270330-index.htm - Executive change Kristian Humer resigned as Director at Sensei Biotherapeutics, Inc.. - Action: resigned - Role: Director source text: effective as of June 12, 2026, Christopher W. Gerry, Thomas Ricks and Kristian Humer resigned from the Board. evidence_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312526270330/0001193125-26-270330-index.htm - Executive change Josiah Craver was appointed as Senior Vice President of Finance and principal accounting officer at Sensei Biotherapeutics, Inc.. - Action: appointed - Role: Senior Vice President of Finance and principal accounting officer source text: Effective as of June 13, 2026, Josiah Craver was ratified as the Company’s Senior Vice President of Finance and appointed as principal accounting officer. evidence_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312526270330/0001193125-26-270330-index.htm - Governance Changes Sensei Biotherapeutics, Inc.: Company filed an amendment to its Amended and Restated Certificate of Incorporation to change its name from Sensei Biotherapeutics, Inc. to Faeth Therapeutics, Inc (effective 2026-06-15). - Change: charter amendment - Effective: 2026-06-15 source text: On June 15, 2026, the Company filed with the Secretary of State of the State of Delaware an amendment to its Amended and Restated Certificate of Incorporation to change the name of the Company from "Sensei Biotherapeutics, Inc." to "Faeth Therapeutics, Inc." (the "Name Change Amendment"). The Name Change Amendment became effective immediately upon filing. evidence_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312526270330/0001193125-26-270330-index.htm - Material Agreements Sensei Biotherapeutics, Inc. terminated Sales Agreement with Jefferies LLC valued at $50,000,000 (effective 2026-06-10). - Action: termination - Agreement: atm program - Counterparty: Jefferies LLC - Value: $50,000,000 - Effective: 2026-06-10 source text: Item 1.02 Termination of a Material Definitive Agreement. As previously disclosed, on March 15, 2022, Faeth Therapeutics, Inc., formerly known as Sensei Biotherapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Prior Sales Agreement”) with Jefferies LLC (“Jefferies”), pursuant to which the Company from time to time may offer and sell shares of its common stock through or to the Agent having an aggregate offering price of up to $50 million. On June 10, 2026, the Company delivered written notice to Jefferies to terminate the Prior Sales Agreement, effective immediately, in accordance with the terms of the Prior Sales Agreement. evidence_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312526270330/0001193125-26-270330-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.